TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05918627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral
Study: NCT01536548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin drawing
Description: Mark direction and angle for cannulation with a pencil on the skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No skin drawing
Description: Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
Study: NCT03772418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream Base
Description: The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomegrante and Ginkgo biloba group
Description: The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
Study: NCT00780286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer based lubricating liquid
Description: 5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moi-Stir
Description: 2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
Study: NCT00558532

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
Study: NCT06320548

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Description: Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Free diet
Description: Patients had free diet.
Study: NCT01113034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAS181 dry powder, formulation F02
Description: 10 mg delivered dose DAS181 in clear HPMC #3 Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Respitose ML006 (DMV-Fonterra)
Description: Lactose monohydrate
Study: NCT03755232

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: scFOS
Description: Fossence™ (short chain Fructo-oligosaccharides (scFOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: scFOS
Description: Fossence™ (short chain Fructo-oligosaccharides (scFOS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: water or dextrose or white bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: water or dextrose or white bread
Study: NCT02984059

Intervention type: GENETIC
Intervention: Genomic DNA
Description: blood draw

Intervention type: GENETIC
Intervention: Genomic DNA
Description: blood draw

Intervention type: GENETIC
Intervention: Genomic DNA
Description: blood draw

Intervention type: GENETIC
Intervention: RNA analysis
Description: Mucosal Biopsy via colonoscopy

Intervention type: GENETIC
Intervention: RNA analysis
Description: Mucosal Biopsy via colonoscopy

Intervention type: GENETIC
Intervention: RNA analysis
Description: Mucosal Biopsy via colonoscopy

Intervention type: GENETIC
Intervention: Microbiome
Description: Stool microbiome

Intervention type: GENETIC
Intervention: Microbiome
Description: Stool microbiome

Intervention type: GENETIC
Intervention: Microbiome
Description: Stool microbiome

Intervention type: OTHER
Intervention: Calprotectin
Description: stool or blood analysis for calprotectin

Intervention type: OTHER
Intervention: Calprotectin
Description: stool or blood analysis for calprotectin

Intervention type: OTHER
Intervention: Calprotectin
Description: stool or blood analysis for calprotectin

Intervention type: OTHER
Intervention: Pain questionnaires
Description: PSDS PCS-C/P PBI APPT

Intervention type: OTHER
Intervention: Pain questionnaires
Description: PSDS PCS-C/P PBI APPT

Intervention type: OTHER
Intervention: Anxiety/Depression Questionnaires
Description: RCADS-25 CSI-24 ARCS

Intervention type: OTHER
Intervention: Anxiety/Depression Questionnaires
Description: RCADS-25 CSI-24 ARCS
Study: NCT04754685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of platelet-rich plasma
Description: The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of platelet-rich plasma
Description: The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of platelet-rich plasma
Description: The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
Study: NCT03876600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Replacement of permanent pacemakers for elective wear.
Description: START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Replacement of permanent pacemakers for elective wear.
Description: START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day.
Study: NCT03242252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral
Study: NCT04286672

Intervention type: DIAGNOSTIC_TEST
Intervention: Metadherin
Description: study alterations of MTDH gene expression in the serum of bladder cancer patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Metadherin
Description: study alterations of MTDH gene expression in the serum of bladder cancer patients
Study: NCT03135925

Intervention type: OTHER
Group type: OTHER
Intervention: Supervised Exercise Program
Description: Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
Study: NCT04603222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUMMIT BRUSH
Description: SUMMIT BRUSH used for the treatment of blepharitis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Description: treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Description: treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Study: NCT03678831

Intervention type: PROCEDURE
Intervention: tissue
Description: Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
Study: NCT05052437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Injection; capecitabine
Description: 8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone
Description: 8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
Study: NCT01287195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral OKT3
Description: 1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg Omeprazole will be given orally to participants once daily for 30 days
Study: NCT01319721

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LCAG
Description: Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMG
Description: Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
Study: NCT00004984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: Capsules oral insulin, 7.5 mg of recombinant human insulin crystals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for oral insulin
Study: NCT03247075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support and Counseling
Description: Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
Study: NCT03099044

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Active dose
Description: Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
Study: NCT01319721

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMG
Description: Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
Study: NCT03099044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double Active dose
Description: Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
Study: NCT02123355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia
Description: Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Induction of anesthesia
Description: Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intubation
Description: After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane, remifentanil ,vecuronium
Description: Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane, remifentanil ,vecuronium
Description: Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
Study: NCT05551624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet
Description: Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
Study: NCT02123355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
Study: NCT04250571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information about No treatment group
Description: Participants will receive no pills and will be told that they are in the no treatment group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaginary pill technique
Description: Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: open label placebo
Description: Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders.
Study: NCT03542435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00840580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution (Vigamox)
Description: One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 0.5% ophthalmic solution (Cravit)
Description: One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
Study: NCT01968057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Administered orally
Study: NCT01116427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: abatacept
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: abatacept
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
Study: NCT00478790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen™ Collagen matrix implantation in glaucoma filtering surgery
Description: ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
Study: NCT03422692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioXclude amnion-chorion membrane
Description: BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mem-Lok collagenous membrane
Description: Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
Study: NCT03913195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab-uiyk
Description: Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab-uiyk
Description: Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab-uiyk
Description: Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
Study: NCT02893124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa
Description: peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
Study: NCT02447094

Intervention type: DRUG
Intervention: Alteplase
Description: Intravenous (i.v.) tPA per the standard of care